Subject category:
Economics, Politics and Business Environment
Published by:
Stanford Business School
Version: 1 April 2007
Length: 16 pages
Data source: Field research
Share a link:
https://casecent.re/p/5813
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
The FDA believed that Prandin was a very innovative drug that would provide the fast growing number of Americans suffering from type II diabetes with a better and more convenient treatment for their health problems. For this reason, the FDA was willing to put Prandin application on the fast track which would allow Novo Nordisk to have the product registered (thus making it legal to sell) in a maximum of 6 months. The decision to schedule the initial worldwide launch of Prandin / Novonorm in the United States in an extremely short time frame was not easy at all.
About
Abstract
The FDA believed that Prandin was a very innovative drug that would provide the fast growing number of Americans suffering from type II diabetes with a better and more convenient treatment for their health problems. For this reason, the FDA was willing to put Prandin application on the fast track which would allow Novo Nordisk to have the product registered (thus making it legal to sell) in a maximum of 6 months. The decision to schedule the initial worldwide launch of Prandin / Novonorm in the United States in an extremely short time frame was not easy at all.